Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13DFiled 13 h ago

Senti Biosciences Holdings, Inc.: New Enterprise Associates 15, L.P. amends Schedule 13D stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13D, sec.gov, 18 November 2026, by SEC EDGAR SCHEDULE 13D

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

New Enterprise Associates 15, L.P. amended its Schedule 13D stake filing for Senti Biosciences Holdings, Inc., per SEC accession 0001072613-26-000911. The filing updates the venture firm's previously reported beneficial ownership position in the gene-circuitry biotech. Schedule 13D amendments are typically triggered by ownership changes, issuer events, or shifts in intent regarding the investment. The revision signals a change in NEA's disclosed position or plans for its Senti stake. Investors will watch for the amended ownership percentage and any stated intent, and for further 13D/A updates or insider transactions.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13D's report. It can get details wrong, so check the source.

Named in this story

New Enterprise Associates 15, L.P., Senti Biosciences Holdings, Inc.